SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid discussions around the potential end of the government shutdown and its impact on the market, with some anticipating a "sell the news" event. Community chatter also revolves around the possible release of the Epstein files and their potential market implications, creating uncertainty and volatility. Additionally, economic data releases are in focus, as the White House suggests October numbers may not be released.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid renewed scrutiny of President Trump's ties to Jeffrey Epstein, with discussions focusing on newly released emails and reports of Trump's efforts to suppress the release of Epstein files. The community is actively debating the implications of these revelations, with some questioning Trump's motives and others defending him against what they claim are politically motivated attacks. This heightened attention coincides with broader market discussions around the stock's fundamentals and potential for volatility.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid anticipation of a potential spot ETF listing on Nasdaq this week, spurring excitement within the community, with some even speculating on significant price increases. Despite general market volatility impacting crypto, the XRP community is focused on the possibility of decoupling from broader market trends and the potential for new investment opportunities through ETFs. Discussions also include perspectives on the regulatory landscape and its impact on XRP's future.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing active discussion around AI valuations and the potential for a tech sector rotation. Community members are debating whether the government shutdown ending will be a "sell the news" event, while also eyeing key technical levels and reacting to intraday price swings. Some traders are closely monitoring potential implications from delayed economic data releases and the unfolding Epstein files.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending amid discussions about its upcoming earnings report and the potential impact of the IPO lock-up period expiring. Community members are debating whether recent selling pressure is a buying opportunity or a sign of further decline, with some anticipating increased volatility. Speculation surrounds potential government contracts and the broader outlook for the stablecoin market.

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Korro Bio ($KRRO) is trending due to mixed reactions to recent news, including restructuring charges and a paused research program alongside the announcement of a $70M private placement. While some investors are wary of these developments, others see the dip as a buying opportunity, citing the company's substantial cash reserves and RNA editing technology. Community discussions revolve around potential for a bounce and comparisons to other companies in the RNA editing space.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to Shah Capital's renewed push for a company sale, citing frustration with underperformance and unmet potential, sparking community debate about management's competence and potential proxy fights. Shareholders are actively discussing the possibility of a buyout and expressing dissatisfaction with the current leadership, particularly regarding partnership progress and market share. The community's sentiment is further fueled by concerns over dilution and the lack of communication from Novavax regarding Shah Capital's concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to recent volatility and a mixed market reaction following earnings and news of a potential 25 million share offering. While some investors express concern about dilution and the stock's recent performance, others view it as a buying opportunity, citing strong long-term growth potential in the AI data center sector and recent deals with major companies. Community discussions revolve around identifying the bottom, with some calling for a rebound and others anticipating further declines.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney ($DIS) is trending amid discussions about its upcoming earnings report and potential performance catalysts. Community members are weighing bullish and bearish perspectives, considering factors like Disney's streaming strategy, theme park performance, and the recent YouTube TV dispute. Some traders are eyeing technical indicators and analyst price targets, while others focus on potential partnerships and upcoming content releases.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco ($CSCO) is trending due to a mixed reaction to its earnings report; while Q4 earnings beat expectations, some analysts are concerned with guidance. The community is debating whether the stock's AI infrastructure growth is enough to offset networking headwinds. Discussions also include potential price targets and comparisons to past market bubbles like the dot-com era, with some seeing a buying opportunity while others remain cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December.&nbsp;</li><li>If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.</li></ul>Shares of Anavex Life Sciences (AVXL) were in the spotlight on Monday as retail investors contemplated the possibilities of a positive take from a European Medicines Agency (EMA) committee for the company’s Alzheimer’s drug Blarcamesine.The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to the agency on human medicines, which the agency uses to approve or reject a drug. On Monday, CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf">included</a> Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13. The oral explanation for Blarcamesine is scheduled for Nov. 11, 2025, at 2:00 p.m.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user is keenly awaiting the statement from Anavex.<stembedurl>https://stocktwits.com/DipperDoo/message/635619033</stembedurl>Another user expressed hope that the committee would be convinced of the drug’s importance following the oral presentation.<stembedurl>https://stocktwits.com/Cresskill198/message/635618141</stembedurl>AVXL shares were down 9% at the time of writing. On Stocktwits, overall retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/57;" src="data:image/png;base64,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" width="587" height="57" alt="AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Anavex’s Application</h2>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Last month, Spirit of the Coast Analytics <a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">noted</a> that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. According to the analyst, the company is “likely” positioned for approval by the EMA in Q4 2025 or Q1 2026. &nbsp;AVXL stock is down by 38% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.

Equity

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.


<ul class="summary-bullets"><li>The pharma major now expects adjusted earnings in the range of $3.00 to $3.15 for the full year.&nbsp;</li><li>Q3 revenue totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues.</li><li>Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand.&nbsp; &nbsp;</li></ul>Pfizer Inc. (PFE) on Tuesday raised its full-year adjusted earnings guidance to a range of $3.00 to $3.15, citing continued confidence in the business and progress with ongoing cost improvement initiatives.The company was previously expecting adjusted earnings in the range of $2.90 to $3.10 per share. Pfizer is now on track to deliver approximately $7.2 billion in overall anticipated net cost savings by the end of 2027, driven by cost improvement initiatives announced previously.The pharma major also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-PFE-Earnings-Release-FINAL.pdf">reaffirmed</a> its full-year revenue guidance of $61.0 billion to $64.0 billion.<h2 class="st-heading-2">Q3 Earnings &nbsp;</h2>For the third quarter, the company reported adjusted earnings per share of $0.87, down from the $1.06 reported in the corresponding period of 2024, but above an analyst estimate of $0.64, according to data from Fiscal AI.Revenue for the three months through the end of September totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues, but above the estimated $16.5 billion.The company’s Paxlovid, an antiviral medication used to treat COVID-19, and its anti-COVID-19 vaccine Comirnaty, saw revenues in the quarter down by 55% and 19%, respectively, on a total basis.Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand. Other drugs to see revenue growth in the quarter include the heart disease drug Vyndaqel, which experienced a 10% increase to $ 1.59 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded 1% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.PFE stock is down 7% this year and approximately 11% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025

The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

<ul class="summary-bullets"><li>Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.</li><li>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price.</li><li>Trian said a mix of third-party equity and debt financing would fund the transaction consideration.</li></ul>Trian Fund Management, Nelson Peltz’s asset management firm, said that the company, along with General Catalyst Group Management, has submitted a non-binding proposal to buy the rest of Janus Henderson Group (JHG) that it does not own for $46.00 per share in cash.U.S.-listed shares of Janus Henderson jumped 18% in early trading on Monday. Trian said that, pursuant to the proposal, a newly formed entity on behalf of General Catalyst and Trian Fund would acquire all of the shares of Janus Henderson not currently owned by Trian.Trian said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.<h2 class="st-heading-2">Price Premium</h2>The per-share price of $46 represents a 10.5% premium over the Oct. 24, 2025, closing price. Trian said that the proposed transaction would derisk an investment that it believes is highly sensitive to capital market and geopolitical dynamics.Trian noted that the per-share price represents an over 56% premium to where the shares traded as recently as this past April, when capital market conditions were less favorable.“When Trian first disclosed its investment in the company in October 2020, the shares were trading at $21.60 per Share, and the company was consistently experiencing outflows in the mid-single digits,” Peltz said in an email to the board of Janus Henderson.“Since that time, the company’s board of directors and management team (led by CEO Ali Dibadj) have achieved a highly successful operational turnaround of the company’s business, which today consistently generates positive net inflows while enjoying mid-30% operating margins,” he added.<h2 class="st-heading-2">Financing Details Of The Proposed Transaction</h2>The transaction consideration would be funded by a mix of equity and debt financing from third parties, including limited partners of Trian and General Catalyst, as well as their affiliated funds, Trian said.“It is our expectation that the board will appoint a special committee of independent, disinterested directors (the “Special Committee”) to consider the proposed transaction and make a recommendation to the Board,” Peltz said.Retail sentiment on Janus Henderson remained unchanged in the ‘bullish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/JHG">Shares of Janus Henderson</a> have gained nearly 16% this year and have jumped over 21% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/organon-ceo-kevin-ali-resigns-audit-probe-into-wholesaler-sales-practices/cLG0eYHR3M8">Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices</a>

Nelson Peltz and Elon Musk attend the Premiere of "Lola" at Regency Bruin Theatre on February 03, 2024 in Los Angeles, California.

JHG Stock Rockets 15% Pre-Market After Receiving A Non-Binding Proposal For $46 Per Share

Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.

<ul class="summary-bullets"><li>Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed.</li><li>The company said that the investigation found these sales represented less than 1% of its consolidated revenue for the year ended Dec. 31, 2022, or Dec. 31, 2024, as applicable.</li><li>Organon said that the board of directors has appointed the company’s Executive Vice President and Head of Manufacturing &amp; Supply, Joseph Morrissey, as its Interim Chief Executive Officer.</li></ul>Organon (OGN) on Monday announced the resignation of Kevin Ali as Chief Executive Officer and a member of the board, in connection with an Audit Committee investigation into sales to wholesalers.Shares of Organon were down nearly 22% in early trading. The company said that after concerns regarding its wholesaler sales practices for its Nexplanon product were brought to the board’s attention, the Audit Committee oversaw an independent, internal investigation into the matter.Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed at the end of the fourth quarter of 2022, the third and fourth quarters of 2024, and the first, second and third quarters of 2025.Retail sentiment on Organon remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Investigation Details</h2>Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed at the end of the fourth quarter of 2022, the third and fourth quarters of 2024, and the first, second, and third quarters of 2025.The company said that the investigation found these sales represented less than 1% of its consolidated revenue for the year ended Dec. 31, 2022, or Dec. 31, 2024, as applicable, but enabled Organon to meet guidance or certain external revenue expectations.Organon noted that the board determined that these wholesaler sales practices were improper and certain of the company’s prior statements were inaccurate or incomplete.“While the findings to date do not necessitate a restatement or revision to any previously issued financial statements, the company is taking remedial actions to improve its financial controls and address any material weaknesses,” Organon said.In connection with the investigation, the company said that it terminated the employment of its Head of U.S. Commercial &amp; Government Affairs, and there has been no finding that the company’s Chief Financial Officer was aware of the improper wholesaler sales practices.<h2 class="st-heading-2">Interim CEO</h2>Organon said that the Board of Directors has appointed the company’s Executive Vice President and Head of Manufacturing &amp; Supply, Joseph Morrissey, as its Interim Chief Executive Officer.The company said Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Morrissey in his new role. The Board is initiating a search for a permanent CEO, including both internal and external candidates, Organon said.<a href="https://stocktwits.com/symbol/OGN">Shares of Organon</a> have declined nearly 48% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/albemarle-to-sell-majority-stake-in-ketjen-s-refining-business-to-kps/cLG0IEGR3MV">Albemarle To Sell Majority Stake In Ketjen’s Refining Catalyst Business To KPS Capital Partners</a>

In this photo illustration, an ORGANON logo is seen displayed on a smartphone and in the background.

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices

Organon said that the investigation found that certain wholesalers in the United States were asked to buy more Nexplanon than they needed.

<ul class="summary-bullets"><li>Albemarle also announced the sale of its entire 50% interest in the Eurecat joint venture to Axens SA.</li><li>The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively.</li><li>Albemarle said that across the two transactions, it expects to receive total pre-tax proceeds of approximately $660 million.</li></ul>Albemarle Corp. (ALB) said on Monday it would sell a controlling stake in Ketjen Corporation's refining catalyst solutions business to KPS Capital Partners.The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively. KPS will hold a majority of the board seats and operational control of Ketjen.Shares of Albemarle were down by more than 2% in premarket trading. The company said it would retain 100% of Ketjen Corporation's Performance Catalyst Solutions business, including its Pasadena, Texas, plant.&nbsp;The company also announced the sale of its entire 50% interest in the Eurecat joint venture to Axens SA. Albermarle noted that both transactions are expected to be completed in the first half of 2026.<h2 class="st-heading-2">Proceeds From The Transactions</h2>The firm said that across the two transactions, it expects to receive total pre-tax proceeds of approximately $660 million, while also retaining about a 49% stake in Ketjen. The company expects to use these proceeds for debt reduction and other general corporate purposes.Retail sentiment on <a href="https://stocktwits.com/symbol/ALB">Albemarle</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Executive View On Stake Sale</h2>CEO of Albemarle Kent Masters said that these transactions align with Albemarle's strategic priorities to focus on its core businesses and competencies, improve financial flexibility, and streamline operations.“Albemarle's retained stake in Ketjen highlights our belief in the business' earnings growth and value creation potential under KPS' direction, and we look forward to partnering with them in driving Ketjen's next phase of growth,” said Masters.Shares of Albemarle have gained nearly 23% this year and about 8% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sotherly-hotels-stock-surge-a-whopping-130-today/cLG0Eu2R3Mi">Why Did Sotherly Hotels' Stock Surge A Whopping 130% Today?</a>

 In this photo illustration, a smartphone displays the logo of Albemarle Corporation (NYSE: ALB). 

Albemarle To Sell Majority Stake In Ketjen’s Refining Catalyst Business To KPS Capital Partners

The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively.

<ul class="summary-bullets"><li>Roger Connor is leaving the role to return to the U.K. to be closer to family, according to a Bloomberg report on Thursday, citing an internal memo.</li><li>Finance executive Ben Eklo will take over as the unit’s CFO starting November 1, the report added.&nbsp;</li><li>Connor’s exit marks the latest management overhaul at the company this year. &nbsp;</li></ul>UnitedHealth Group’s (UNH) Optum unit’s CFO, Roger Connor, is reportedly leaving the role less than six months into the role.According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-23/unitedhealth-s-optum-unit-gets-second-new-cfo-in-six-months">report</a> on Thursday, citing an internal memo, Connor is leaving the role to return to the U.K. to be closer to family. Finance executive Ben Eklo will take over as the unit’s CFO starting November 1, the report added. Eklo has been with UnitedHealth for 18 years.Connor, however, will stay on at the company through April to ensure a transition, the memo reportedly said. He was appointed Optum CEO in May. The memo also described several other changes in finance roles in the company’s business units, including at Optum Health and for UnitedHealthcare’s government insurance plans, Bloomberg added.<h2 class="st-heading-2">Optum’s Significance</h2>UnitedHealth’s Optum division includes its pharmacy benefits business, a portfolio of medical clinics and in-home care programs, and a data and technology unit.In July, the company said it expects total Optum revenue of $266 billion to $267.5 billion and operating earnings of $12.55 billion to $12.85 billion for the full year 2025. In the three months through the end of June, the division reported revenue of $67.2 billion and earnings from operations of $3.1 billion.<h2 class="st-heading-2">Management Shake-Ups This Year</h2>Connor’s exit marks the latest management overhaul at UNH this year. Andrew Witty withdrew from his CEO role in May, citing personal reasons, and was <a href="https://stocktwits.com/news-articles/markets/equity/unitedhealth-shareholder-propoes-distinct-chairman-chief-executive-roles-report/chCuNwfR3Qa">replaced</a> by Stephen Hemsley. The company also <a href="https://stocktwits.com/news-articles/markets/equity/united-health-s-cfo-shake-up-doesn-t-deter-retail-bulls-traders-call-stock-a-2018-level-opportunity/chr3k1VRdGi">named</a> Wayne DeVeydt as CFO in July, replacing John F. Rex.The management shakeups follow other crises at the insurance company. In July, the insurer issued fresh guidance for full-year revenue of $445.5 billion to $448.0 billion and adjusted earnings of at least $16.00 per share, after suspending its previous outlook in May due to higher medical costs. The company had previously forecast adjusted profit of $29.50 to $30.00 per share, nearly double its latest forecast.<a href="https://stocktwits.com/symbol/UNH">UNH shares</a> fell 1% on Thursday afternoon at the time of writing. On Stocktwits, retail sentiment around UNH rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:622/57;" src="data:image/png;base64,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" width="622" height="57"><figcaption>UNH's Sentiment Meter and Message Volume as of 12:18 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>UNH stock is down by 29% this year and by 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-solutions-stock-rises-on-new-contract-for-drug-testing-technology/cLG4mupR3rX">Intelligent Bio Solutions Stock Rises On New Contract For Drug Testing Technology</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

 UnitedHealth’s Optum CFO Reportedly Exits In Less Than Six Months Into The Role

Roger Connor is leaving the role to return to the U.K. to be closer to family, according to a Bloomberg report on Thursday, citing an internal memo.

<ul class="summary-bullets"><li>Applied Digital said that this was a nearly 15-year lease agreement to deliver 200 MW of critical IT capacity at Polaris Forge 2.</li><li>The company noted that the 200 MW&nbsp;capacity would support the hyperscaler’s artificial intelligence (AI) and high-performance compute (HPC) infrastructure.&nbsp;</li><li>Applied Digital’s total leased capacity with two hyperscalers across its Polaris Forge 1 and Polaris Forge 2 campuses in North Dakota has now reached 600 MW.</li></ul>Applied Digital (APLD) shares jumped nearly 7% before the bell on Wednesday after the company announced a $5 billion AI factory lease with a U.S.-based investment-grade hyperscaler at Polaris Forge 2 campus, currently under construction near Harwood, North Dakota.&nbsp;The company said this was a nearly 15-year lease agreement to deliver 200 megawatts (MW) of critical IT capacity at Polaris Forge 2 to support the hyperscaler’s artificial intelligence (AI) and high-performance compute (HPC) infrastructure.&nbsp;Retail sentiment on <a href="https://stocktwits.com/symbol/APLD">Applied Digital</a> improved to ‘bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.<h2 class="st-heading-2">What To Know About Applied Digital’s AI Factory Lease</h2>Applied Digital said the Hyperscaler also holds a first right of refusal for an additional 800 MW of critical IT, representing the full expansion potential of the 1-gigawatt (GW) Polaris Forge 2 Campus.The company said that with this agreement, Applied Digital’s total leased capacity with the two hyperscalers across its Polaris Forge 1 and Polaris Forge 2 campuses in North Dakota has now reached 600 MW.<h2 class="st-heading-2">Polaris Forge 2</h2>The company said that the Polaris Forge 2 spans more than 900 acres and is engineered to deliver efficiency with a projected power usage effectiveness of 1.18 and near-zero water consumption.Applied Digital stated that the initial 200 MW will be phased across two buildings, with operations expected to begin in 2026 and reach full capacity by 2027. The campus is designed for future expansion.This follows Applied Digital's announcement of an additional 150MW lease with CoreWeave at its Polaris Forge 1 Campus, as well as a $5.0 billion AI infrastructure partnership with Macquarie Asset Management.Shares of Applied Digital have gained 316% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nhl-signs-multiyear-licensing-deals-with-kalshi-polymarket-report/cLG5edGR3qd">NHL Signs Multiyear Licensing Deals With Kalshi, Polymarket: Report</a>

In this photo illustration, a smartphone displays the logo of Applied Digital Corporation (NASDAQ: APLD) on July 28, 2025, in Chongqing, China. 

Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler

Applied Digital said that this was a nearly 15-year lease agreement to deliver 200 MW of critical IT capacity at Polaris Forge 2.

Hillenbrand (HI) announced on Wednesday that it has entered into a definitive agreement to be acquired by an affiliate of Lone Star Funds in an all-cash transaction valuing the company at $3.8 billion.Shares of Hillenbrand jumped nearly 19% in premarket trading after the company said it would be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price of $23.43 on August 12. The transaction is expected to close by the end of the first quarter of calendar year 2026.Retail sentiment on <a href="https://stocktwits.com/symbol/HI">Hillenbrand</a> improved to ‘neutral’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.&nbsp;“The Board carefully reviewed a range of potential strategic alternatives, including interest from a number of parties, and determined that this transaction is in the best interest of Hillenbrand and its shareholders,” said Helen Cornell, Chairperson of the Board of Directors.Hillenbrand said that once the deal is closed, it will become a privately held company, and the company’s shares will no longer trade on the New York Stock Exchange. Shares of the company traded nearly 3% higher in Wednesday’s pre-market session.The company said during its fourth-quarter results that it would not be issuing financial guidance for fiscal year 2026.Hillenbrand is known for providing processing equipment and solutions to customers around the world through its Advanced Process Solutions and Molding Technology Solutions segments.&nbsp;Shares of Hillenbrand have declined nearly 14% this year and have fallen 6% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dollar-tree-stock-rising-today/ch6nw5IR3NW">Why Is Dollar Tree Stock Rising Today?</a>

Hillenbrand To Go Private In Nearly $4B Deal With Affiliate Of Lone Star Funds

The company will be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price on August 12.

iShares Trust - iShares ESG Aware 60/40 Balanced Allocation ETF

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF